- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyT Seck
Merck Research Laboratories, Rahway, NJ, USA
Int J Clin Pract 64:562-76. 2010..To evaluate the 2-year safety and efficacy of adding sitagliptin or glipizide to ongoing metformin in patients with type 2 diabetes...
- Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizideThomas L Seck
Merck Sharp and Dohme Corp, Whitehouse Station, NJ, United States
Diabetes Res Clin Pract 93:e15-7. 2011..5% without hypoglycemia and without an increase in body weight...